FMP
NASDAQ
3 USD
0.0401 (1.34%)
Mr. David T. Domzalski
Healthcare
Biotechnology
https://www.vynetherapeutics.com
NASDAQ
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo...
0001566044
US92941V3087
92941V209
520 U.S. Highway 22
800 775 7936
US
10
Jan 25, 2018
0001566044
NASDAQ
Biotechnology
Healthcare
92941V209
US92941V3087
US
3
1.41
125.36k
42.3M
-
1.67-8.73
2.67
-
-
-
-
-1.1
-
https://www.vynetherapeutics.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.